



EXPRESS MAIL NO.: EV 473 972 056 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Flechtner et al. Confirmation No.: 7221
Application No.: 10/820,067 Art Unit: 1648
Filed: April 8, 2004 Examiner: Blumel, Benjamin P.
For: HEAT SHOCK PROTEIN-BASED Attorney Docket No.: 8449-406-999
VACCINES AND IMMUNOTHERAPIES

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references **B19** and **B20** which are listed on the attached List of References Cited by Applicant. A copy of references **B19** and **B20** is submitted herewith. These references were cited in a Supplementary European Search Report, dated June 27, 2007, for a counterpart European application.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is being filed after the period specified in 37 C.F.R. § 1.97(c), but on or before the payment of the issue fee.
08/22/2007 SSANDR00000027 503013 11820067

01 FC:1806 180.00 DA

NYI-4012467v1

7 -

In accordance with 37 C.F.R. § 1.97(d)(1) and (e)(1), the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

In accordance with 37 C.F.R. § 1.97(d) and § 1.17(p), the fee required has been estimated to be \$180.00. Please charge the required fee to Jones Day Deposit Account No. ~~50-3010~~. A copy of this sheet is enclosed.

U.S.C. 50-3013

Respectfully submitted,

Date: August 13, 2007

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)
JONES DAY
222 E. 41st Street
New York, New York 10017
(212) 326-3939



AUG 13 2007

Express Mail No.: EV 473 972 056 US
Sheet 1 of 1 of List of ReferencesLIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-406-999	APPLICATION NO. 10/820,067
APPLICANT Flechtner et al.	
FILING DATE April 8, 2004	ART UNIT 1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	B19	WO 2001/78772	10/25/01	Mojave Therapeutics, Inc.	
	B20	WO 2004/071457	8/26/04	Mojave Therapeutics, Inc.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	